DO-10

Indicaton

GM1-gangliosidosis and mucopolysaccharidosis IVB, 2 rare diseases caused by beta-galactosidase deficiency.

Therapeutic indications

Metabolic disorder

Type of product

Small molecule

Table

Phase

Discovery
Available in

EU, US, Japan

You may also be interested in

TOP-N53, TOP-N44, TOP-M119, TOP-V122, TOP-T5

Clinical development for diabetic foot ulcer and digital ulcer. Preclinical development burn wounds, normal tension glaucoma, hair growth and chemotherapy induced hair loss, prevention of colorectal cancer, Elimination of cancer stem cells and skin aging.

Phase I started

TOTIPHARMACEUTICAL

Polypharmacology for all therapeutic aeras using nano-drug delivery systems

TOP-N53, TOP-N44, TOP-N73a, TOP-N73b, TOP-N73c

Topadur has invented and pioneered dual mode of action low molecular weight drugs, which increase microcirculation and capillary perfusion. The unique mode of mechanism translates into a so far unsurpassed potency and efficacy, which enables therapies for several high medical need indications.